STOCKS · DIVIDENDS · EARNINGS

FNREPORT.COM

Finance & Numbers

미국주식, 배당주, 실적발표와 쉬운 알고리즘 트레이딩을 한눈에 정리합니다. 투자 판단에 필요한 핵심 데이터와 인사이트를 쉽게 확인해보세요.

벡톤 디킨슨 앤 코 (BDX) 주가 전망: 목표주가, 배당, 최신 뉴스

2026-08-09T06:05:31.147Z
벡톤 디킨슨 앤 코 (BDX) 주가 전망: 목표주가, 배당, 최신 뉴스
섹션 바로가기클릭하면 해당 섹션으로 이동합니다

벡톤 디킨슨 앤 코 (BDX) 회사 소개

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.

It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems.

It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.

It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Becton, Dickinson and Company는 전 세계의 의료기관, 의사, 생명과학 연구자, 임상검사실, 제약업계 및 일반 소비자를 대상으로 의료용 소모품, 기기, 실험실 장비 및 진단제품을 개발·제조·판매합니다. 사업은 Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences의 4개 세그먼트로 운영됩니다.

제품 포트폴리오는 peripheral intravenous (IV) 및 advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extension sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems 등을 포함합니다. 또한 IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, medication inventory optimization and tracking system, hemodynamic monitoring system, prefillable drug delivery systems 등 약물관리 및 주입 관련 솔루션을 제공합니다. 검사 관련으로는 specimen and blood collection products, automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, rapid diagnostic assays, microbiology laboratory automation products, plated media products 및 fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, solution for single-cell gene expression analysis, 임상종양·면역·이식 진단·모니터링 시약과 분석기 등이 포함됩니다.

또한 hernia and soft tissue repair, biological and bioresorbable graft, biosurgery 및 기타 외과용 제품과 surgical infection prevention, peripheral intervention, urology and critical care 제품도 제공합니다. 회사는 의료현장의 유해약물 오염 검사 개선을 위해 ChemoGLO와 전략적 협업을 진행하고 있으며, 1897년에 설립되어 본사는 뉴저지주 Franklin Lakes에 있습니다.

  • 주소: 1 Becton Drive, Franklin Lakes, NJ 07417-1880, United States

  • 전화번호: 201 847 6800

  • 웹사이트: https://www.bd.com

  • 섹터: Healthcare

  • 산업: Medical Instruments & Supplies

  • 직원 수: 72,000

BDX STOCK CHART

BDX 주가 차트 (1년)

차트 로딩 중...

벡톤 디킨슨 앤 코 BDX LATEST NEWS

최신뉴스: 2일 전

BDX LATEST NEWS

벡톤 디킨슨 앤 코 최신 뉴스

벡톤 디킨슨 앤 코 관련 주요 소식과 시장 반응

BDX DIVIDEND HISTORY

BDX DIVIDEND INFORMATION

BDX 배당정보

최근 배당 정보Finviz Dividend Snapshot

배당락일Sep 09, 2026
예상 연배당3.99
TTM 배당3.98
배당 수익률Dividend Yield
2.22%TTM 3.98
연간 배당금Annual Dividend
3.99Est. 2.23%
P/E 비율P/E Ratio
54.06
배당성향Payout Ratio
71.53%
Dividend Est.Finviz가 제공하는 예상 연간 배당금과 예상 배당수익률입니다.
Dividend TTM최근 12개월 기준 배당금과 배당수익률입니다.
Dividend Gr. 3/5Y최근 3년/5년 배당 성장률입니다.
항목값
Dividend Est.3.99 (2.23%)
Dividend TTM3.98 (2.22%)
Dividend Ex-DateSep 09, 2026
Dividend Gr. 3/5Y6.13% 5.65%
Payout71.53%
P/E54.06

배당 지급 이력Dividend payout history

배당락일Ex-date배당금Amount특별배당Special
Sep 9, 20261.050.00
Jun 9, 20261.050.00
Mar 10, 20261.050.00
Feb 10, 20260.0044.41
Dec 8, 20250.830.23
Sep 8, 20250.820.22
Jun 9, 20250.820.22
Mar 10, 20250.820.22
Dec 9, 20240.820.22
Sep 9, 20240.750.20

BDX TARGET PRICE 2026

BDX TARGET PRICE

BDX 목표주가

BDX에 대한 월가 애널리스트들의 평가! 최근 목표가 변화와 투자 의견을 한눈에 확인해보세요.
🕒 마지막 업데이트2026/07/28(59일 전)
날짜의견애널리스트투자의견목표가 변경
Jul-28-26신규InitiatedUBS
매수
Buy
$19
May-04-26분석 재개ResumedEvercore ISI
시장수익률상회
Outperform
$180
Apr-10-26분석 재개ResumedGoldman
중립
Neutral
$167
Feb-10-26분석 재개ResumedBarclays
비중확대
Overweight
$202
Feb-03-26분석 재개ResumedCitigroup
매수
Buy
$233
Sep-25-25신규InitiatedRBC Capital Mkts
Sector Perform
$211
May-22-25하향DowngradeCitigroup
Buy → Neutral
$185
May-02-25하향DowngradeRaymond James
Outperform → Mkt Perform
May-02-25하향DowngradePiper Sandler
Overweight → Neutral
$185
May-02-25하향DowngradeGoldman
Buy → Neutral
$192
May-01-25하향DowngradeWilliam Blair
Outperform → Mkt Perform
May-01-25하향DowngradeWells Fargo
Overweight → Equal Weight
May-01-25하향DowngradeBofA Securities
Buy → Neutral
$190
Oct-01-24상향UpgradeCitigroup
Neutral → Buy
$255 → $275
May-30-24신규InitiatedGoldman
매수
Buy
$274
Jul-24-23상향UpgradeRaymond James
Mkt Perform → Outperform
$305
May-30-23분석 재개ResumedMorgan Stanley
비중확대
Overweight
$295
May-05-23상향UpgradePiper Sandler
Neutral → Overweight
$260 → $290
Apr-12-23상향UpgradeKeyBanc Capital Markets
Sector Weight → Overweight
$304
Jan-03-23상향UpgradeBofA Securities
Neutral → Buy
$250 → $290
✍️ 최근 5일 BDX 차트분석
BDX 매물대 데이터를 불러오는 중...

벡톤 디킨슨 앤 코 (BDX) 차트분석

벡톤 디킨슨 앤 코의 최근 5일 흐름, 단기 매물대, 이동평균 저항/지지와 시뮬레이션 차트는 별도 차트분석 페이지에서 확인할 수 있습니다.

차트분석 페이지 보기

벡톤 디킨슨 앤 코 (BDX) 최근 실적발표

벡톤 디킨슨 앤 코의 EPS, 매출, 실적 발표일과 관련 차트는 내부 실적발표 페이지에서 확인할 수 있습니다.

실적발표 페이지 보기